ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Share Price Pass Above Fifty Day Moving Average – What’s Next?

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $93.06 and traded as high as $97.00. ProShares Ultra Nasdaq Biotechnology shares last traded at $96.08, with a volume of 3,676 shares trading hands.

ProShares Ultra Nasdaq Biotechnology Stock Down 0.5%

The firm has a market capitalization of $80.71 million, a price-to-earnings ratio of 20.68 and a beta of 1.19. The company has a fifty day moving average price of $93.06 and a two-hundred day moving average price of $86.65.

Institutional Investors Weigh In On ProShares Ultra Nasdaq Biotechnology

Large investors have recently modified their holdings of the stock. Kaizen Financial Strategies raised its position in ProShares Ultra Nasdaq Biotechnology by 4.7% during the 1st quarter. Kaizen Financial Strategies now owns 5,565 shares of the exchange traded fund’s stock worth $483,000 after buying an additional 250 shares during the last quarter. Citadel Advisors LLC purchased a new position in ProShares Ultra Nasdaq Biotechnology in the third quarter valued at about $307,000. Finally, Franklin Resources Inc. purchased a new position in ProShares Ultra Nasdaq Biotechnology in the second quarter valued at about $32,000.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.